Evidence map›Paper›PMID 37542303›Full record

ArticleCell & bioscience2023

The interwoven fibril-like structure of amyloid-beta plaques in mouse brain tissue visualized using super-resolution STED microscopy.

Björn Johansson, Sho Oasa, Aida Muntsant Soria, Ann Tiiman, Linda Söderberg, Ebba Amandius, Christer Möller, Lars Lannfelt, Lars Terenius, Lydia Giménez-Llort and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell & bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Björn JohanssonDepartment of Clinical Neuroscience, Karolinska Institutet, SE-17176, Stockholm, Sweden.
Sho OasaDepartment of Clinical Neuroscience, Karolinska Institutet, SE-17176, Stockholm, Sweden.
Aida Muntsant SoriaInstitut de Neurociències, Universitat Autònoma de Barcelona, 08193, Barcelona, Spain.
Ann TiimanDepartment of Clinical Neuroscience, Karolinska Institutet, SE-17176, Stockholm, Sweden.
Linda SöderbergBioArctic AB, Stockholm, Sweden.
Ebba AmandiusBioArctic AB, Stockholm, Sweden.
Christer MöllerBioArctic AB, Stockholm, Sweden.
Lars LannfeltBioArctic AB, Stockholm, Sweden.
Lars TereniusDepartment of Clinical Neuroscience, Karolinska Institutet, SE-17176, Stockholm, Sweden.
Lydia Giménez-LlortInstitut de Neurociències, Universitat Autònoma de Barcelona, 08193, Barcelona, Spain.
Vladana VukojevićDepartment of Clinical Neuroscience, Karolinska Institutet, SE-17176, Stockholm, Sweden. vladana.vukojevic@ki.se.ORCID http://orcid.org/0000-0003-0873-5653
BioArctic Neuroscience (Sweden) · SEKarolinska Institutet · SEUniversitat Autònoma de Barcelona · ESKarolinska University Hospital · SE

Funding

HORIZON EUROPE Reforming and enhancing the European Research and Innovation system No. 737390Magnus Bergvalls Stiftelse 2021-04376Stiftelsen Olle Engkvist Byggmästare 199-0480UAB-GE-26408 UAB-GE-26408Vetenskapsrådet 2018-05337Vetenskapsrådet 2022-03402
6 · The paper itself

Abstract

backgroundStandard neuropathologic analysis of Alzheimer's brain relies on traditional fluorescence microscopy, which suffers from limited spatial resolution due to light diffraction. As a result, it fails to reveal intricate details of amyloid plaques. While electron microscopy (EM) offers higher resolution, its extensive sample preparation, involving fixation, dehydration, embedding, and sectioning, can introduce artifacts and distortions in the complex brain tissue. Moreover, EM lacks molecular specificity and has limited field of view and imaging depth.

resultsIn our study, we employed super-resolution Stimulated Emission Depletion (STED) microscopy in conjunction with the anti-human APP recombinant antibody 1C3 fluorescently labelled with DyLight

conclusionsThe utilization of STED microscopy represents a groundbreaking advancement in the field, enabling researchers to delve into the characterization of local mechanisms that underlie Amyloid (Aβ) deposition into plaques and their subsequent clearance. This unprecedented level of detail is especially crucial for comprehending the etiology of Alzheimer's disease and developing the next generation of anti-amyloid treatments. By facilitating the evaluation of drug candidates and non-pharmacological interventions aiming to reduce amyloid burden, STED microscopy emerges as an indispensable tool for driving scientific progress in Alzheimer's research.

Indexed as

Alzheimer’s diseaseAmyloid beta peptideAmyloid fibrilsImmunohistochemistryNext generation drug designSuper-resolution STED microscopy

Identifiers

PMID37542303
PMCPMC10403925
OpenAlexW4385576151

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.